Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06644937
NCT06644937RecruitingPhase 2

Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Zhujiang Hospital1 site in 1 country30 target enrollmentStarted: November 29, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
1 year recurrence-free survival rate ,1-year RFSR.
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The subjects voluntarily cooperated with the study and signed the informed consent,
  • •Male or female, 18 years old ≤ age ≤75 years old,
  • •The histopathologic diagnosis was hepatocellular carcinoma
  • •R0 resection was performed within 4 to 8 weeks before recruitment (patients who were confirmed to have R0 resection by imaging and pathological examination were excluded from the study group if the residual R1, residual R2 or the margin of resection were not clear)
  • •To satisfy any of the following high risk factors for postoperative recurrence of hepatocellular carcinoma:
  • •I) BCLC stage B (> 3 tumors, regardless of size or number, at least one of which is > 3 cm in diameter) ; ii) single tumor ≥5 cm in diameter; III) intraoperative or postoperative pathological findings of vascular invasion (including microvascular invasion and VP1/VP2 portal vein invasion) ; IV) histopathologic grade of low differentiation; v) capsular invasion or loss with unclear border; VI) direct invasion of adjacent organs
  • •ECOG performance status score of 0-1 and Child-Pugh score of 5-6
  • •None of the patients had received anti-tumor therapy for hepatocellular carcinoma, including systemic therapy and local therapy (except for 1-2 prophylactic TACE or HAIC 4-8 weeks after radical therapy) .
  • •Subjects who received radical therapy, if required, were allowed to receive 1-2 prophylactic TACE/Haic treatments 4-8 weeks after surgery (on demand and not necessarily)

Exclusion Criteria

  • •Known sarcomatoid hepatocellular carcinoma/mixed hepatocellular carcinoma-cholangiocarcinoma/fibrolamellar hepatocellular carcinoma;
  • •A history of other malignancies in the past 5 years or at the same time;
  • •Severe functional impairment of other important organs such as heart, brain, lung and kidney;
  • •Patients with a history of immunodeficiency or autoimmune disease;
  • •Evidence of tumor recurrence or metastasis before enrollment;
  • •Known hypersensitivity to active ingredients, excipients, or history of severe allergy to any other monoclonal antibody, anti-angiogenic drugs;
  • •Patients with a history of hepatic encephalopathy;

Arms & Interventions

TACE combination with icaritin

Experimental

Intervention: TACE combined with Acoradine (Drug)

Outcomes

Primary Outcomes

1 year recurrence-free survival rate ,1-year RFSR.

Time Frame: 1 year

1 year recurrence-free survival rate ,1-year RFSR.

Secondary Outcomes

  • TTR( time to recurrence)(1year)

Investigators

Sponsor
Zhujiang Hospital
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 2
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma
NCT00522405All India Institute of Medical Sciences, New Delhi
Completed
Not Applicable
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by SorafenibCarcinoma, Hepatocellular
NCT01933945Bayer1,676
Completed
Phase 2
TACTICSHepatocellular carcinoma(HCC)Chemotherapy, Hepatocellular carcinoma(HCC), TACE
JPRN-jRCTs031180074Kudo Masatoshi62
Completed
Phase 2
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
NCT04511455Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest22
Unknown
Not Applicable
Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCCHepatocellular Carcinoma
NCT03243916Chinese PLA General Hospital40
Single-arm Clinical Trial of TACE in... | Clinical Trial